Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSS11
- Development stage
- Phase 1
- Lead developer
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Administration
- Intravenous (injection)
01
Overview
SSS11 is a pegylated recombinant form of the enzyme uricase (urate oxidase) derived from the yeast Candida utilis. It is being developed as an injectable treatment for gout and hyperuricemia, particularly in patients who have elevated serum uric acid levels and may not respond adequately to conventional oral therapies. The drug works by catalyzing the oxidation of uric acid to allantoin, a more soluble compound that can be more easily excreted by the kidneys, thereby lowering serum urate levels. PEGylation (attachment of polyethylene glycol chains) increases its half-life and reduces immunogenicity compared to non-PEGylated forms[1][2][4]. Clinical trials are ongoing to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with gout/hyperuricemia[1][2][4].
- Brand names
- SSS11SSS-11SSS 11
- Other names
- Pegylated recombinant Candida utilis uricasePegylated recombinant Candida urate oxidasePegylated recombinant Candida uricase for injection
Beyond the preview
Go deeper on SSS11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSS11.